necitumumab,telisotuzumab
nippon kayaku,eli lilly,abbvie
['sclc', 'lcsm,(-blcsm)', 'biomarker', 'nsclc', 'necitumumab']
great discussion by on osi combinations in egfr+ metastatic #nsclc after progression on tkis. teliso v+osi (met inhibition) shows promising activity; necitumumab+osi shows modest activity. importance of biomarker selection in this group? #asco22 #lcsm 
LUNGevity Foundation is dedicated to funding lung cancer research and providing support to ALL people affected by lung cancer.